Edge-AI Diagnostics Deployment Leader

The mandate

The executive leading an edge-assisted diagnostic rollout began unplanned medical leave as devices reached forty new partner sites. Installations continue, but model versions, calibration, connectivity fallback and clinician escalation differ by site, and no single leader currently has authority to halt expansion or reconcile field performance with the signed clinical-use boundary.

The interim must begin in Nairobi within three weeks and hold the deployment seat for twelve months. A permanent search starts after two representative site clusters complete a full quality cycle, expected in month seven, with six weeks reserved for the successor to observe field release and then chair the last regional readiness council.

Handover requires every active device to have traceable configuration and calibration, priority site classes to remain within signed diagnostic and referral corridors for two review cycles, offline and synchronisation recovery to pass witnessed tests, critical incidents to close, and the permanent appointee to accept the next two-quarter rollout map. Installation count alone is not completion.

The interim may pause sites or model versions, set configuration standards, redirect field engineering, appoint temporary country leads and reallocate up to KES 420 million within the approved rollout. New diagnostic claims, changes to clinical-use boundaries, permanent leadership hires, country entry and spend above KES 120 million per decision require committee approval; local clinicians retain patient decisions.

New assay research, hospital information-system replacement, commercial pricing and general clinic operations are outside scope. The remit covers device and model deployment, calibration, offline behaviour, evidence flow, field service, partner readiness and the decision controls needed for accountable regional scale.

Why this seat is open

An unexpected health absence removed the only executive joining clinical evidence to distributed technology operations. Continuing the same rollout speed would multiply site variance before quality leaders can see it. Temporary leadership is needed to stabilise existing deployment and leave a measured system for the returning or permanently appointed executive.

What you will own

• Reconcile every active device to hardware, model, calibration, reference range, connectivity, operator and site-readiness evidence.
• Define site classes and release criteria for workflow, prevalence, environment, power, network, operator training and referral capacity.
• Decide which installations, models or use cases pause when diagnostic, calibration, data-integrity or clinical-escalation evidence fails.
• Establish offline inference and delayed-synchronisation controls that prevent stale configuration, duplicate records and silent loss of review.
• Build field monitoring around calibration drift, abstention, discordance, referral completion, device failure and operator intervention.
• Command site drills covering power loss, connectivity interruption, suspect calibration, urgent finding and controlled return to service.
• Transfer the device registry, site risk map, clinical decisions, supplier obligations and rollout calendar through a successor-led council.

Candidate qualifications

• Held executive or enterprise-director responsibility for deployed AI diagnostics, connected medical devices or distributed laboratory technology.
• Scaled devices across low-connectivity clinical settings while controlling configuration, calibration, model version and operator competence.
• Paused a clinical technology rollout after site evidence diverged from validation and can describe the safe restoration decision.
• Built monitoring that connected model performance to discordance, referral, patient pathway and device-operating conditions.
• Governed local clinician authority, central product decisions and country quality responsibilities across several health systems.
• Handed a distributed diagnostic platform to permanent leadership with tested field-service, incident and release controls.

Non-negotiables

• Can start in Nairobi within three weeks, work on site initially and travel monthly to a designated regional clinic or laboratory hub.
• Accepts that qualified clinicians retain patient decisions and that model output cannot expand beyond the approved use boundary.
• Brings direct clinical deployment accountability; consumer wellness AI or central laboratory analytics alone is insufficient.
• Must disclose diagnostic-device, laboratory, health-system and model-provider relationships before site data is shared.

1. 49 words maximum. State your earliest Nairobi start and any obligation incompatible with full-time deployment authority.
2. 49 words maximum. Describe a site condition that invalidated an AI diagnostic rollout and the evidence required to restart.
3. 49 words maximum. Which offline or calibration signal would make you quarantine an otherwise functioning device?